Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $5.5 million.

  • ImmunityBio's Change in Accured Expenses fell 1215.87% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$855000.0, marking a year-over-year increase of 9547.86%. This contributed to the annual value of -$1.5 million for FY2024, which is 12254.45% down from last year.
  • As of Q3 2025, ImmunityBio's Change in Accured Expenses stood at $5.5 million, which was down 1215.87% from $8.7 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Change in Accured Expenses registered a high of $18.6 million during Q1 2023, and its lowest value of -$19.5 million during Q4 2023.
  • For the 5-year period, ImmunityBio's Change in Accured Expenses averaged around $827578.9, with its median value being $3.3 million (2024).
  • As far as peak fluctuations go, ImmunityBio's Change in Accured Expenses soared by 67533.02% in 2022, and later plummeted by 51935.89% in 2023.
  • Over the past 5 years, ImmunityBio's Change in Accured Expenses (Quarter) stood at $4.6 million in 2021, then plummeted by 169.13% to -$3.2 million in 2022, then tumbled by 519.36% to -$19.5 million in 2023, then soared by 89.17% to -$2.1 million in 2024, then skyrocketed by 358.7% to $5.5 million in 2025.
  • Its last three reported values are $5.5 million in Q3 2025, $8.7 million for Q2 2025, and -$12.9 million during Q1 2025.